RT @CADTH_ACMTS: Differences in Incremental Cost-Effectiveness Ratios for Common vs Rare Conditions: A Case from Oncology /via PharmacoEcon…
RT @CADTH_ACMTS: Differences in Incremental Cost-Effectiveness Ratios for Common vs Rare Conditions: A Case from Oncology /via PharmacoEcon…
Differences in Incremental Cost-Effectiveness Ratios for Common vs Rare Conditions: A Case from Oncology /via PharmacoEconomics-Open https://t.co/ihZfKkjvGp #HealthEconomics
RT @ETS_IECS: Drugs treating rare cancers have not different ICERs than drugs treating common cancer ♋ https://t.co/SOxjFzauM6
Drugs treating rare cancers have not different ICERs than drugs treating common cancer ♋ https://t.co/SOxjFzauM6
Rare cancers just as likely to have cost-effective ICERs https://t.co/vfWGgbiUp3
RT @HealthEconBot: #HealthEconJA Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from … http…
#HealthEconJA Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from … https://t.co/zyj5qgPMpk